UPDATE: Milestone Pharmaceuticals (MIST) - $200M War Chest and Slaying the Hypotension Bear

Earnings confirm the launch runway is fully funded through 2027. Plus, new ACC data puts the biggest safety concern to bed.

Mar 21, 2026

∙ Paid

The News: The Scoreboard is Live

Milestone Pharmaceuticals dropped a flurry of updates this week, including their Q4 and full-year 2025 financial results, an update on the CARDAMYST launch, and new clinical data presented at the American College of Cardiology (ACC.26) Scientific Session.

If you’ve been tracking my previous coverage, you know we are officially out of the binary regulatory risk phase and deep into the commercial execution phase. Here is how the latest updates stacks up against the core thesis.

Continue reading this post for free, courtesy of Biotech Distilled.

Or purchase a paid subscription.